uniQure (NASDAQ:QURE) Research Coverage Started at StockNews.com

Stock analysts at StockNews.com started coverage on shares of uniQure (NASDAQ:QURE – Get Rating) in a research note issued on Thursday. The firm set a “hold” rating on the biotechnology company’s stock.

QURE has been the subject of several other research reports. Credit Suisse Group boosted their target price on shares of uniQure from $51.00 to $55.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 28th. Truist Financial cut their price objective on uniQure from $65.00 to $55.00 in a research note on Thursday, May 11th. HC Wainwright restated a “buy” rating and set a $90.00 price objective on shares of uniQure in a research note on Tuesday, March 7th. Guggenheim restated a “buy” rating and set a $53.00 price objective on shares of uniQure in a research note on Tuesday, February 28th. Finally, 1-800-FLOWERS.COM restated a “maintains” rating on shares of uniQure in a research note on Tuesday. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $55.71.

uniQure Stock Up 2.8 %

Shares of NASDAQ QURE opened at $20.56 on Thursday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 6.56 and a current ratio of 6.67. uniQure has a 1 year low of $12.83 and a 1 year high of $28.25. The stock’s 50-day simple moving average is $19.98 and its 200-day simple moving average is $21.38. The firm has a market cap of $978.24 million, a price-to-earnings ratio of -6.16 and a beta of 1.18.

uniQure (NASDAQ:QURE – Get Rating) last posted its quarterly earnings data on Monday, February 27th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $1.04. uniQure had a negative return on equity of 35.03% and a negative net margin of 143.01%. The company had revenue of $102.75 million for the quarter, compared to the consensus estimate of $55.37 million. As a group, equities analysts anticipate that uniQure will post -4.77 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Matthew C. Kapusta sold 2,521 shares of the firm’s stock in a transaction that occurred on Tuesday, March 7th. The stock was sold at an average price of $21.39, for a total value of $53,924.19. Following the sale, the chief executive officer now owns 468,743 shares of the company’s stock, valued at approximately $10,026,412.77. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In the last 90 days, insiders have sold 5,919 shares of company stock valued at $126,208. Insiders own 3.10% of the company’s stock.

Institutional Trading of uniQure

Hedge funds have recently made changes to their positions in the stock. BlackRock Inc. raised its stake in uniQure by 14.0% during the 3rd quarter. BlackRock Inc. now owns 4,898,640 shares of the biotechnology company’s stock valued at $91,897,000 after acquiring an additional 599,805 shares in the last quarter. Point72 Asset Management L.P. raised its stake in uniQure by 11.5% during the 3rd quarter. Point72 Asset Management L.P. now owns 4,259,886 shares of the biotechnology company’s stock valued at $79,915,000 after acquiring an additional 440,186 shares in the last quarter. State Street Corp raised its stake in uniQure by 29.5% during the 3rd quarter. State Street Corp now owns 3,063,265 shares of the biotechnology company’s stock valued at $57,467,000 after acquiring an additional 698,121 shares in the last quarter. PFM Health Sciences LP raised its stake in uniQure by 7.0% during the 3rd quarter. PFM Health Sciences LP now owns 2,393,311 shares of the biotechnology company’s stock valued at $44,899,000 after acquiring an additional 156,941 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in uniQure by 10.9% during the 3rd quarter. Vanguard Group Inc. now owns 1,434,004 shares of the biotechnology company’s stock valued at $26,903,000 after acquiring an additional 141,382 shares in the last quarter. Institutional investors own 88.03% of the company’s stock.

About uniQure

(Get Rating)

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.